Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

489 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Long GV, et al. Among authors: grob jj. Ann Oncol. 2019 Nov 1;30(11):1848. doi: 10.1093/annonc/mdz221. Ann Oncol. 2019. PMID: 31406976 Free PMC article. No abstract available.
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Long GV, et al. Among authors: grob jj. Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176. Ann Oncol. 2017. PMID: 28475671 Free PMC article. Clinical Trial.
Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006.
Long GV, Arance A, Mortier L, Lorigan P, Blank C, Mohr P, Schachter J, Grob JJ, Lotem M, Middleton MR, Neyns B, Steven N, Ribas A, Walpole E, Carlino MS, Lebbe C, Sznol M, Jensen E, Leiby MA, Ibrahim N, Robert C. Long GV, et al. Among authors: grob jj. Ann Oncol. 2022 Feb;33(2):204-215. doi: 10.1016/j.annonc.2021.10.010. Epub 2021 Oct 25. Ann Oncol. 2022. PMID: 34710571 Free article. Clinical Trial.
Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine.
Grob JJ, Amonkar MM, Martin-Algarra S, Demidov LV, Goodman V, Grotzinger K, Haney P, Kämpgen E, Karaszewska B, Mauch C, Miller WH Jr, Millward M, Mirakhur B, Rutkowski P, Chiarion-Sileni V, Swann S, Hauschild A. Grob JJ, et al. Ann Oncol. 2014 Jul;25(7):1428-1436. doi: 10.1093/annonc/mdu154. Epub 2014 Apr 25. Ann Oncol. 2014. PMID: 24769640 Free article. Clinical Trial.
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).
Saiag P, Gutzmer R, Ascierto PA, Maio M, Grob JJ, Murawa P, Dreno B, Ross M, Weber J, Hauschild A, Rutkowski P, Testori A, Levchenko E, Enk A, Misery L, Vanden Abeele C, Vojtek I, Peeters O, Brichard VG, Therasse P. Saiag P, et al. Among authors: grob jj. Ann Oncol. 2016 Oct;27(10):1947-53. doi: 10.1093/annonc/mdw291. Epub 2016 Aug 8. Ann Oncol. 2016. PMID: 27502712 Free PMC article. Clinical Trial.
Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA; BRIM-3 Study Group. Chapman PB, et al. N Engl J Med. 2011 Jun 30;364(26):2507-16. doi: 10.1056/NEJMoa1103782. Epub 2011 Jun 5. N Engl J Med. 2011. PMID: 21639808 Free PMC article. Clinical Trial.
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
Kandolf Sekulovic L, Peris K, Hauschild A, Stratigos A, Grob JJ, Nathan P, Dummer R, Forsea AM, Hoeller C, Gogas H, Demidov L, Lebbe C, Blank C, Olah J, Bastholt L, Herceg D, Neyns B, Vieira R, Hansson J, Rutkowski P, Krajsova I, Bylaite-Bucinskiene M, Zalaudek I, Maric-Brozic J, Babovic N, Banjin M, Putnik K, Weinlich G, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Kukushkina M, De La Cruz Merino L, Ymeri A, Risteski M, Garbe C. Kandolf Sekulovic L, et al. Among authors: grob jj. Eur J Cancer. 2017 Apr;75:313-322. doi: 10.1016/j.ejca.2017.01.012. Epub 2017 Mar 4. Eur J Cancer. 2017. PMID: 28264791 Free article.
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial.
Hughes BGM, Munoz-Couselo E, Mortier L, Bratland Å, Gutzmer R, Roshdy O, González Mendoza R, Schachter J, Arance A, Grange F, Meyer N, Joshi A, Billan S, Zhang P, Gumuscu B, Swaby RF, Grob JJ. Hughes BGM, et al. Among authors: grob jj. Ann Oncol. 2021 Oct;32(10):1276-1285. doi: 10.1016/j.annonc.2021.07.008. Epub 2021 Jul 20. Ann Oncol. 2021. PMID: 34293460 Free article. Clinical Trial.
489 results